11.07.16
Regeneron
3Q Revenues: $1.2 billion (7%)
3Q Earnings: $265.0 million (+26%)
YTD Revenues: $3.6 billion (+21%)
YTD Earnings: $642.4 million (+34%)
Comments: Product sales were $857 million in the quarter, up 16%. Sales of EYLEA in the U.S. increased 16% to $854 million in the quarter. Sales of Praluent were $38 million, compared to $4 million in 3Q15 when the product was launched in the U.S. Product sales for Praluent are recorded by Sanofi, and the company shares in any profits or losses from the commercialization of Praluent. R&D expenses were $543 million in the quarter, up 27% primarily related to the $25 million up-front payment in connection with the Adicet collaboration.
3Q Revenues: $1.2 billion (7%)
3Q Earnings: $265.0 million (+26%)
YTD Revenues: $3.6 billion (+21%)
YTD Earnings: $642.4 million (+34%)
Comments: Product sales were $857 million in the quarter, up 16%. Sales of EYLEA in the U.S. increased 16% to $854 million in the quarter. Sales of Praluent were $38 million, compared to $4 million in 3Q15 when the product was launched in the U.S. Product sales for Praluent are recorded by Sanofi, and the company shares in any profits or losses from the commercialization of Praluent. R&D expenses were $543 million in the quarter, up 27% primarily related to the $25 million up-front payment in connection with the Adicet collaboration.
